News of Note—Clementia IPO; Eloxx series C; Collidion-Plex stake

Investment is the name of the game in today's news of note.

> Following on from a spate of biotech public offerings in recent months, ultrarare bone disease biotech Clementia has priced its IPO at the high end at $15 a pop, bringing in a chunky $120 million. Insiders bought about a quarter of the shares. The Canadian biotech plans to use the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Release

> Eloxx Pharmaceuticals has gained an additional $8 million investment by LSP, a healthcare investor, boosting its series C to $38 million. The funds will be put toward its work on genetic diseases caused by nonsense mutations. Statement

> And it's money news galore as Collidion and Plex Pharmaceuticals have penned a new deal that sees Collidion get its hands on an 80% equity stake in Plex in exchange for an “undisclosed amount of cash and contributing a novel drug asset under development.” The pact also sees Collidion give “management and operational support” as Plex works on meds for Parkinson's disease, glioblastoma and cataracts. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.